Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

Recruiting

Phase 1

Loncastuximab Tesirine & VenetoclaxLoncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

Sponsor:

Paolo Caimi, MD

Code:

NCT05053659

Conditions

Relapsed Non Hodgkin Lymphoma

Refractory Non-Hodgkin Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Loncastuximab tesirine

Venetoclax

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-18. This information was provided to ClinicalTrials.gov by Paolo Caimi, MD on 2025-08-06.